rHuPH20 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dermatitis, Allergic Contact

Conditions

Dermatitis, Allergic Contact

Trial Timeline

Jun 23, 2009 → Sep 13, 2009

NCT ID

NCT00928447

About rHuPH20 + Placebo

rHuPH20 + Placebo is a phase 2 stage product being developed by Halozyme Therapeutics for Dermatitis, Allergic Contact. The current trial status is completed. This product is registered under clinical trial identifier NCT00928447. Target conditions include Dermatitis, Allergic Contact.

What happened to similar drugs?

20 of 20 similar drugs in Dermatitis, Allergic Contact were approved

Approved (20) Terminated (0) Active (0)

✅LebrikizumabEli LillyApproved

✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved

✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved

✅tacrolimusAstellas PharmaApproved

✅tacrolimus ointment + placebo ointmentAstellas PharmaApproved

✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved

✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00928447	Phase 2	Completed	Jun 23, 2009	Sep 13, 2009	Dermatitis, Allergic Contact

Competing Products

20 competing products in Dermatitis, Allergic Contact

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab	Eli Lilly	Phase 3	40
Baricitinib + Placebo + Topical corticosteroid	Eli Lilly	Phase 3	40
Lebrikizumab	Eli Lilly	Approved	50
Lebrikizumab	Eli Lilly	Phase 3	40
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin	Hoth Therapeutics	Phase 1	19
Lebrikizumab	Eli Lilly	Phase 3	40
ASN008	Formation Bio	Phase 2	25
ENS-002	Concerto Biosciences	Phase 1	11
nemolizumab (CIM331)	Chugai Pharmaceutical	Phase 2	35
DS-2741a + Placebo	Daiichi Sankyo	Phase 1	21
SUN13834 + Placebo	Daiichi Sankyo	Phase 2	35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061	Daiichi Sankyo	Phase 2	35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%	Astellas Pharma	Phase 2	35
tacrolimus ointment	Astellas Pharma	Phase 3	40
tacrolimus 0.1% + fluticasone 0.005 %	Astellas Pharma	Approved	43
tacrolimus ointment + pimecrolimus cream	Astellas Pharma	Approved	43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAX	Astellas Pharma	Phase 2	35
tacrolimus	Astellas Pharma	Approved	43
Tacrolimus Ointment 0.1%	Astellas Pharma	Phase 2	35